KI-Beratung Beta

Produktbild: THERAPEUTIC PROTEIN DRUG PRODU
Band 6

THERAPEUTIC PROTEIN DRUG PRODU

143,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Therapeutic protein drug products provides a comprehensive overview of therapeutic protein drug products, with an emphasis on formulation beginning in the laboratory, followed by manufacturing and administration in the clinic. A list of many commercial therapeutic drug products are described and include...

Beschreibung

Therapeutic protein drug products provides a comprehensive overview of therapeutic protein drug products, with an emphasis on formulation beginning in the laboratory, followed by manufacturing and administration in the clinic. A list of many commercial therapeutic drug products are described and include the product name, dosages, active concentration, buffer, excipients, Ph, container type and route of administration. The laboratory formulation sections focus on the most common buffers, excipients, and Ph ranges that are commonly tested in addition to systematic approaches. A brief section on biophysical and analytical analysis is also provided. Properties of therapeutic protein formulations are described and include opalescence, phase separation, color, and subvisible particles. An emphasis is placed on material and process testing to ensure success during manufacturing. The drug product manufacturing process, which includes the process of compounding to filling, is also covered. Methods of delivery in the clinic are addressed, as well as delivery strategies. Finally, a perspective on the regulatory requirements for therapeutic protein formulations is discussed.

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

02.01.2012

Herausgeber Brian K. Meyer
Verlag Elsevier Science & Technology

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

02.01.2012

Herausgeber Brian K. Meyer
Verlag Elsevier Science & Technology
Seitenzahl

200

Maße (L/B/H)

23,4/15,5/23,3 cm

Gewicht

480 g

Sprache

Englisch

ISBN

978-1-907568-18-3

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: THERAPEUTIC PROTEIN DRUG PRODU
  • List of figures and tables

    Preface

    About the authors

    Chapter 1: Commercial therapeutic protein drug products

    Abstract

    1.1 Introduction

    1.2 Lyophilized formulations

    1.3 Liquid formulations

    1.4 Protein formulations for radiologic and diagnostic use

    1.5 Summary

    Chapter 2: A formulation method to improve the physical stability of macromolecular-based drug products

    Abstract

    2.1 Introduction

    2.2 Common techniques used for the construction of EPDs

    2.3 The peptide drug pramlintide

    2.4 Monoclonal antibodies at low and high concentration

    2.5 Static vs. dynamic EPDs: a case study using a humanized immunoglobulin (IgG1)

    2.6 Conclusion and future studies

    Chapter 3: Properties of protein formulations

    Abstract

    3.1 Introduction

    3.2 Opalescence

    3.3 Phase separation

    3.4 Color

    3.5 Subvisible particles

    Chapter 4: Material and process compatibility testing

    Abstract

    4.1 Introduction

    4.2 Material compatibility

    4.3 Process compatibility testing

    4.4 Antimicrobial preservative compatibility testing

    Chapter 5: Compounding and filling: drug substance to drug product

    Abstract

    5.1 Introduction

    5.2 Aseptic processing

    5.3 Bulk drug substance

    5.4 Compounding of drug product

    5.5 Filling the drug product

    Chapter 6: Administration in the clinic

    Abstract

    6.1 Introduction and background

    6.2 Diluents

    6.3 Components

    6.4 Construction materials

    6.5 Clinical dosing strategy: fixed volume versus fixed concentration

    6.6 Representative admixture concentration levels

    6.7 Exposure temperature and time

    6.8 Option of using syringes

    6.9 Analytical tests and acceptance criteria

    6.10 Sample preparation considerations

    6.11 Role of probe studies

    6.12 Bag overfill volume

    6.13 Pharmacy instructions

    6.14 Conclusions

    Chapter 7: Regulatory guidelines for the development of a biotechnology drug product

    Abstract

    7.1 Introduction

    7.2 ICH overview

    7.3 Common Technical Document (CTD)

    7.4 Drug product dossier

    7.5 Regulatory considerations through the biotechnology product lifecycle

    7.6 Conclusions

    Appendix

    Recommended reading

    Index